Wave, Life Sciences and Duchenne muscular dystrophy
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.
Just as F1 teams rely on real-time data to optimize performance, IoT is enabling life sciences manufacturers to achieve new ...
Klick Health today announced the round two results of its $1,000,000 Klick Prize after awarding a combined $200,000 to four ...
Former Fed chairman Alan Greenspan coined the phrase "irrational exuberance" to describe the risk of unduly escalated asset ...
GlobalData on MSN1d
ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drugThe primary goals of the study are to evaluate the safety and overall response rate in patients who are given RLS-0071.
The Chicago battery startup announced plans to expand to Flint, Michigan, last week on the heels of a $60 million grant from ...
Five life sciences companies are expanding their operations in Connecticut, including several that are leasing space in the ...
1d
H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his ...
Richmond’s Activation Capital is launching a pre-accelerator program focused on early-stage founders working in biotech and ...
Projects focus on cancer therapies, robotic clot removal catheters, and mRNA vaccines, among other technologies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback